170 related articles for article (PubMed ID: 15166272)
1. CDX-2 immunostaining in primary and secondary ovarian carcinomas.
Tornillo L; Moch H; Diener PA; Lugli A; Singer G
J Clin Pathol; 2004 Jun; 57(6):641-3. PubMed ID: 15166272
[TBL] [Abstract][Full Text] [Related]
2. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769
[TBL] [Abstract][Full Text] [Related]
4. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
Kim MJ
J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
[TBL] [Abstract][Full Text] [Related]
5. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
6. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
7. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
[TBL] [Abstract][Full Text] [Related]
8. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.
Chou YY; Jeng YM; Kao HL; Chen T; Mao TL; Lin MC
Histopathology; 2003 Aug; 43(2):151-6. PubMed ID: 12877730
[TBL] [Abstract][Full Text] [Related]
10. CDX-2 expression in pulmonary fine-needle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma.
Levine PH; Joutovsky A; Cangiarella J; Yee H; Simsir A
Diagn Cytopathol; 2006 Mar; 34(3):191-5. PubMed ID: 16470859
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
12. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
13. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases.
Raspollini MR; Amunni G; Villanucci A; Baroni G; Taddei A; Taddei GL
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):127-31. PubMed ID: 15354737
[TBL] [Abstract][Full Text] [Related]
14. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.
Ji H; Isacson C; Seidman JD; Kurman RJ; Ronnett BM
Int J Gynecol Pathol; 2002 Oct; 21(4):391-400. PubMed ID: 12352188
[TBL] [Abstract][Full Text] [Related]
17. Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel.
Raspollini MR; Baroni G; Taddei A; Taddei GL
Arch Pathol Lab Med; 2003 Dec; 127(12):1586-90. PubMed ID: 14632574
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.
Raspollini MR; Nesi G; Baroni G; Girardi LR; Taddei GL
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):358-62. PubMed ID: 16280666
[TBL] [Abstract][Full Text] [Related]
19. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma.
Kennedy MT; Jordan RC; Berean KW; Perez-Ordoñez B
J Clin Pathol; 2004 Sep; 57(9):932-7. PubMed ID: 15333652
[TBL] [Abstract][Full Text] [Related]
20. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas.
Yatabe Y; Koga T; Mitsudomi T; Takahashi T
J Pathol; 2004 Jun; 203(2):645-52. PubMed ID: 15141379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
